Effect of 1% Povidone Iodine Mouthwash/Gargle, Nasal and Eye Drop in COVID-19 patient
Dr Md Iqbal, Mahmud Choudhury, Nilufar Shabnam, Tazin Ahsan, Rashed Md Khan, S M Abu Ahsan
Background: The sudden onset of COVID-19 began in late 2019 caused by a novel coronavirus (SARS-COV2) and on 11th March, WHO declared it to have developed pandemic status. There is still no specific treatment and vaccine available for COVID-19; causing wide spread health problem and concern of the globe. Povidone iodine (PVP-I) is an antiseptic that has been used for over 150 years. It is already proved that different concentration of PVP-I can deactivate COVID-19 virus. Methodology: In this randomized controlled clinical trial, out of 1113 patients 606 patients were enrolled and divided in 2 groups by randomization after taken consents. In Gr-A, 303 patients underwent mouthwash/gargle, nasal drops and eye drops with 1% povidone iodine 4 hourly for 4 weeks as well as symptomatic treatment according to need. In Gr-B 303 patients were advised mouthwash/gargle, nasal cavity and eye wash with lukewarm water 4 hourly for 4 weeks and symptomatic treatment according to need. RT-PCR test done every 3rd, 5th and 7th day and Thyroid hormone level (TSH,T 3 , T 4, FT 4 ) at 4th week for follow up. Results: The group of patients used 1% PVP-I have shown tremendously reduced mortality, morbidity and hospital as well as financial burden in this covid situation. Conclusion: Administration of 1% PVP-I as mouthwash/gargle, nasal or eye drop is simple, rapid and cost effective in reduction of mortality and morbidity by COVID-19.
References
Ader, Paul, Reinhardt, Safran, Pino et al., Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on iodine absorption and thyroid function, The Journal of Clinical Endocrinology & Metabolism
Bigliardi, Alsagoff, El-Kafrawi, Pyon, Wa et al., Povidone iodine in wound healing: A review of current concepts and practices, International Journal of Surgery
Cascella, Rajnik, Cuomo, Dulebohn, Napoli, Features, evaluation and treatment coronavirus (COVID-19)
Cooper, Iodine revisited, International wound journal
Da Silveira Teixeira, De Figueiredo, Cherubini, De Oliveira, Salum, The topical effect of chlorhexidine and povidone-iodine in the repair of oral wounds. A review, Stomatologija
Domingo, Farrales, Loya, Uy, The effect of 1% povidone iodine as a pre-procedural mouthrinse in 20 patients with varying degrees of oral hygiene, The Journal of the Philippine Dental Association
Eggers, Eickmann, Zorn, Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA), Infectious diseases and therapy
Eggers, Eickmann, Zorn, Rapid and effective virucidal activity of povidone-iodine products against Middle East respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus Ankara (MVA), Infectious diseases and therapy
Eggers, Infectious disease management and control with povidone iodine, Infectious diseases and therapy
Eggers, Koburger-Janssen, Eickmann, Zorn, In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens, Infectious diseases and therapy
Eggers, Koburger-Janssen, Eickmann, Zorn, In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/mouthwash against respiratory and oral tract pathogens, Infectious diseases and therapy
Hamid, Khurshid, Adanir, Zafar, Zohaib, COVID-19 Pandemic and Role of Human Saliva as a Testing Biofluid in Point-of-Care Technology, European Journal of Dentistry
Hou, Okuda, Edwards, Martinez, Asakura et al., SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract, Cell
Kanagalingam, Feliciano, Hah, Labib, Lin, Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections, International journal of clinical practice
Kariwa, Fujii, Takashima, Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents, Dermatology
Kawana, Kudo, A trial of povidone-iodine (PVP-I) nasal inhalation and gargling to remove potentially pathogenic bacteria colonized in the pharynx. Kansenshogakuzasshi. The Journal of the Japanese Association for Infectious Diseases
Khurshid, Asiri, Wadaani, Human saliva: Noninvasive fluid for detecting novel coronavirus (2019-nCoV), International Journal of Environmental Research and Public Health
Kirk-Bayley, Challacombe, Sunkaraneni, Combes, The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current COVID-19 Pandemic May Protect Healthcare Workers and Reduce Cross Infection
Kirk-Bayley, Combes, Sunkaraneni, Challacombe, The use of Povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers
Koerner, George, Meyer, Rosco, Habib, Povidone-iodine concentration and dosing in cataract surgery, Survey of ophthalmology
Lange, Wolf, Auw-Haedrich, Schlecht, Boneva et al., Expression of the COVID-19 receptor ACE2 in the human conjunctiva, Journal of Medical Virology
Lu, Zhao, Li, Niu, Yang et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, The Lancet
Martínez, Diz, Pérez, Del, Cabrera et al., Is povidone iodine mouthwash effective against SARS-CoV-2.First in vivo tests. Oral diseases
Parikh, Bly, Bonilla-Velez, Dahl, Evans et al., Pediatric otolaryngology divisional and institutional preparatory response at Seattle Children's Hospital after COVID-19 regional exposure, Otolaryngology-Head and Neck Surgery
Park, Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2
Pelletier, Tessema, Westover, Frank, Brown et al., In Vitro Efficacy of Povidone-Iodine Nasal And Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). medRxiv
Pelletier, Tessema, Westover, Frank, Brown et al., In Vitro Efficacy of Povidone-Iodine Nasal And Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). medRxiv
Sarma, Kaur, Kaur, Bhattacharyya, Prajapat et al., Ocular manifestations and tear or conjunctival swab PCR positivity for 2019-nCoV in patients with COVID-19: a systematic review and meta-analysis
Sarma, Prajapat, Avti, Kaur, Kumar et al., Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach, Indian journal of pharmacology
Shiraishi, Nakagawa, Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations, Dermatology
Silas, Schroeder, Thomson, Myers, Optimizing the antisepsis protocol: Effectiveness of 3 povidoneiodine 1.0% applications versus a single application of povidoneiodine 5.0%, Journal of Cataract & Refractive Surgery
To, Tsang, Yip, Chan, Wu et al., Consistent detection of 2019 novel coronavirus in saliva, Clinical Infectious Diseases
Urias, Varghese, Simunich, Morrissey, Dumire, Preoperative decolonization to reduce infections in urgent lower extremity repairs, European Journal of Trauma and Emergency Surgery
Van, Bushmaker, Morris, Holbrook, Gamble et al., Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, New England Journal of Medicine
Wada, Nojima, Ogawa, Hayashi, Sugiyama et al., Relationship between virucidal efficacy and free iodine concentration of povidone-iodine in buffer solution, Biocontrol Science
Walls, Park, Tortorici, Wall, Mcguire et al., Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, Cell
Wang, Chen, Zhou, Lian, Zhang et al., SARS-CoV-2 invades host cells via a novel route: CD147-spike protein, BioRxiv
Wu, Duan, Luo, Liu, Qu et al., Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, JAMA ophthalmology
Wölfel, Corman, Guggemos, Seilmaier, Zange et al., Virological assessment of hospitalized patients with COVID-2019, Nature
Yan, Zhang, Li, Xia, Guo et al., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2, Science
Zheng, SARS-CoV-2: an emerging coronavirus that causes a global threat, International journal of biological sciences
Zou, Ruan, Huang, Liang, Huang et al., SARS-CoV-2 viral load in upper respiratory specimens of infected patients, New England Journal of Medicine
{ 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T12:29:11Z', 'timestamp': 1711801751297},
'reference-count': 0,
'publisher': 'Bangladesh Journals Online (JOL)',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2021, 6, 23]],
'date-time': '2021-06-23T00:00:00Z',
'timestamp': 1624406400000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc/4.0'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>Background: The sudden onset of COVID-19 began in late 2019 caused by a novel '
'coronavirus (SARS-COV2) and on 11th March, WHO declared it to have developed pandemic status. '
'There is still no specific treatment and vaccine available for COVID-19; causing wide spread '
'health problem and concern of the globe. Povidone iodine (PVP-I) is an antiseptic that has '
'been used for over 150 years. It is already proved that different concentration of PVP-I can '
'deactivate COVID-19 virus.
\n'
'Methodology: In this randomized controlled clinical trial, out of 1113 patients 606 patients '
'were enrolled and divided in 2 groups by randomization after taken consents. In Gr-A, 303 '
'patients underwent mouthwash/gargle, nasal drops and eye drops with 1% povidone iodine 4 '
'hourly for 4 weeks as well as symptomatic treatment according to need. In Gr-B 303 patients '
'were advised mouthwash/gargle, nasal cavity and eye wash with lukewarm water 4 hourly for 4 '
'weeks and symptomatic treatment according to need. RT-PCR test done every 3rd, 5th and 7th '
'day and Thyroid hormone level (TSH,T3, T4, FT4) at 4th week for follow up.
\n'
'Results: The group of patients used 1% PVP-I have shown tremendously reduced mortality, '
'morbidity and hospital as well as financial burden in this covid situation.
\n'
'Conclusion: Administration of 1% PVP-I as mouthwash/gargle, nasal or eye drop is simple, '
'rapid and cost effective in reduction of mortality and morbidity by COVID-19.
\n'
'Bioresearch Commu. 7(1): 919-923, 2021 (January)</jats:p>',
'DOI': '10.3329/brc.v7i1.54245',
'type': 'journal-article',
'created': {'date-parts': [[2021, 6, 29]], 'date-time': '2021-06-29T06:49:52Z', 'timestamp': 1624949392000},
'page': '919-923',
'source': 'Crossref',
'is-referenced-by-count': 13,
'title': 'Effect of 1% Povidone Iodine Mouthwash/Gargle, Nasal and Eye Drop in COVID-19 patient',
'prefix': '10.3329',
'volume': '7',
'author': [ {'given': 'Md Iqbal Mahmud', 'family': 'Choudhury', 'sequence': 'first', 'affiliation': []},
{'given': 'Nilufar', 'family': 'Shabnam', 'sequence': 'first', 'affiliation': []},
{'given': 'Tazin', 'family': 'Ahsan', 'sequence': 'first', 'affiliation': []},
{'given': 'Md Saiful', 'family': 'Kabir', 'sequence': 'first', 'affiliation': []},
{'given': 'Rashed', 'family': 'Md Khan', 'sequence': 'first', 'affiliation': []},
{'given': 'SM Abu', 'family': 'Ahsan', 'sequence': 'first', 'affiliation': []}],
'member': '1861',
'published-online': {'date-parts': [[2021, 6, 23]]},
'container-title': 'Bioresearch Communications',
'original-title': [],
'link': [ { 'URL': 'https://www.banglajol.info/index.php/BRC/article/download/54245/37954',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.banglajol.info/index.php/BRC/article/download/54245/37954',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2021, 6, 29]],
'date-time': '2021-06-29T06:50:05Z',
'timestamp': 1624949405000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.banglajol.info/index.php/BRC/article/view/54245'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 6, 23]]},
'references-count': 0,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2021, 6, 29]]}},
'URL': 'http://dx.doi.org/10.3329/brc.v7i1.54245',
'relation': {},
'ISSN': ['2411-0272', '2411-0485'],
'container-title-short': 'Bioresearch Communications',
'published': {'date-parts': [[2021, 6, 23]]}}
